论文部分内容阅读
许多哮喘患者虽定期治疗,但静止时支气管仍持续收缩,可能气道内存在持续性致痉介质。作者通过随机双盲对照试验,研究了半胱氨酰白三烯受体阻断剂ICI204219对哮喘患者支气管持续性收缩的作用.11例稳定性轻、中度哮喘患者参加了试验.治疗前6周无哮喘或无呼吸道感染恶化,随机双官法给予ICI204219(40mg)或安慰剂,每隔30分钟测FEV_1和SGaw 共4小时.吸入舒喘灵气雾剂(2ml 内含5mg)15分钟后测定FEV_1和SGaw。
Although many asthmatic patients are treated regularly, the bronchus continues to contract at rest and may have persistent spasm mediators in the airways. The authors studied the effect of ICI204219, a cysteinyl leukotriene receptor blocker, on bronchial persistent contraction in asthmatic patients through a randomized, double-blind, controlled trial.11 patients with stable mild to moderate asthma participated in the trial.6 Week without asthma or no worsening of respiratory tract infection, ICI204219 (40 mg) or placebo was randomized to double doses of FEV 1 and SGaw for 4 hours every 30 minutes, 15 minutes after inhalation of Shuqinling Aerosol (2ml contained 5mg) FEV_1 and SGaw.